Bank Julius Baer & Co
SUPN icon

Bank Julius Baer & Co’s Supernus Pharmaceuticals SUPN Stock Holding History

Bank Julius Baer & Co’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-665
Closed -$21K – 626
2022
Q1 		$21K Buy
+665
New +$20.4K ﹤0.01% 555

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Bank Julius Baer & Co's SUPN Position: Q2 2022 in Review

Bank Julius Baer & Co sold out of Supernus Pharmaceuticals (SUPN) in Q2 2022, closing a stake of 665 shares — an estimated $21K sold.

Bank Julius Baer & Co first reported a position in SUPN in Q1 2022 and held it in 1 quarter. The position peaked at $21K in Q1 2022. 225 funds tracked by Wall St. Rank hold SUPN as of Q2 2022.

  • Bank Julius Baer & Co reported no remaining Supernus Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Bank Julius Baer & Co sold 665 Supernus Pharmaceuticals shares in Q2 2022, an estimated $21K.
  • Bank Julius Baer & Co first reported a position in Supernus Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Bank Julius Baer & Co's Supernus Pharmaceuticals position peaked at $21K in Q1 2022.
  • 225 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2022.

Based on Bank Julius Baer & Co's 13F filing for Q2 2022, filed 22 Jul 2022.